Selected SLC Research


Webinar | December 11, 2012

The Meningitis Outbreak and the Regulation of Compounding Companies: Federal and State Roles

Jeremy Williams

This webinar, presented by CSG’s Southern Legislative Conference, focused on the recent meningitis outbreak and the ensuing federal and state responses.  In early October 2012, reports of fungal meningitis began popping up in clusters throughout the nation.  By 2013, the disease affected more than 540 people across 19 states and caused 36 deaths.  The outbreak is attributed to the use of contaminated steroids—and possibly two other drugs—made by a compounding pharmacy in Massachusetts, which according to federal investigative reports, was operating outside the boundaries of it its compounding license.  The pharmacy was shut down.  More than two months following the initial recall of the steroid, the U.S. Centers for Disease Control and Prevention is still receiving reports of infection.

The federal government and state health departments have begun assessing what measures can be taken to avoid future outbreaks, such as strengthening efforts to regulate compounding pharmacies and by coordinating initiatives to share information and strategies.  At the forefront of these efforts are health officials in Michigan and Tennessee, states that have seen the highest reported number of cases of meningitis in the country, who believe measures can be taken to avoid future incidents.

Presenters
  • Mr. Jim Collins, Director, Communicable Disease Division, Michigan Department of Community Health
  • Christopher R. Braden, MD, Director, Division of Foodborne, Waterborne and Environmental Diseases, U.S. Centers for Disease Control and Prevention
  • Carmen Catizone, Executive Director/Secretary, National Association of Boards of Pharmacy
Presentations

The Meningitis Outbreak and the Regulation of Compounding Companies: Federal and State Roles

Archived Webinar

View it here.